cancer target screening
cancer target screening
Revolutionary Munich Company Doses First Patient with Groundbreaking Cancer Treatment
BIOT
📢 Tubulis from Munich doses first patient with its ADC candidate TUB-040 targeting NaPi2b antigen in ovarian and lung cancer. 🧪
Curve Therapeutics Secures £405m in Funding to Revolutionize Cancer Treatment
BIOT
📢 Curve Therapeutics secures £40.5m in funding led by Pfizer Ventures to advance cancer target screening and peptide pipeline! 💪🔬
